09 August 2017
Visiongain has launched a new pharma report The Next Generation Sequencing Market Forecast 2017-2027: Revenue Prospects by Application (Drug Discovery, Genetic Screening, Diagnostics, Personalized Medicine, Agriculture And Animal Research, Infectious Diseases, Others) Technology (Whole-Genome Sequencing, Targeted Re-Sequencing, Exome Sequencing, RNA Seq, Chip Seq, De Novo Sequencing, Methyl Seq, Others), Products (Instruments, Reagents & Consumables, Services), End User (Hospital & Healthcare Institution, Academics, Biotechnology, Pharmaceutical, Others) and Geography
Next-Generation Sequencing (NGS), also known as high-throughput sequencing, can be defined as a process used to sequence DNA strands in parallel and substantially minimize the need for fragment cloning which are used in methods such as Sanger sequencing. NGS is a powerful platform that has enabled the sequencing of millions of DNA molecules whilst simultaneously significantly reducing the cost. With the use of NGS an entire human genome can be sequenced in a day. NGS can be used to sequence entire genomes or constrained to specific areas of interest, including all 22 000 coding genes (a whole exome) or small numbers of individual genes. The data output of NGS has out placed Moore’s Law more than doubling each year.
The development of NGS technologies over the past few years have made large-scale projects such as the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) feasible. The technique has provided multi-platform data for thousands of tumours from a variety of cancer types and subtypes as well as integrative analyses of genomic, transcriptomic and epigenomic data, thereby increasing our understanding of cancer biology.
The lead Visiongain report analyst for this report commented; “The market for next generation sequencing is mainly driven by factors such as technological advancements in sequencing platforms, increasing applications of next generation sequencing, growing number of partnerships and collaborations, increasing adoption of next generation sequencing technologies among research laboratories and academic institutes. The application of next generation sequencing in a diverse range of medical conditions will provide new growth opportunities to key players in the next generation sequencing market.”
The Next Generation Sequencing market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the global next generation sequencing market include Illumina, Inc., Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., Qiagen N.V., Beijing Genomics Institute, Perkinelmer, Inc., F. Hoffmann-La Roche AG, Agilent Technologies, Inc., Gatc Biotech AG, Oxford Nanopore Technologies, Ltd., Macrogen, Inc. and Eurofins Scientific.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Increasing demand for medical products in developing as well developed economies coupled with rising ageing population is expected to open new opportunities for medical device contract manufacturing industry over the forecast period.
01 December 2020
With the growing burden of rare diseases around the world, there has been a rise in the requirement for proper diagnosis as well as full proof treatment positions for various chronic diseases. With increasing awareness regarding symptoms of various terminal illnesses, the diagnosis rates have been improving in developing countries such as China, India, Japan, Brazil, and other southeast Asian countries.
01 December 2020
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.
30 November 2020
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.